The use of reimbursement data are particularly appropriate in this setting because inferences can be made about BC biology due to the specificity of treatments, such as endocrine therapy and anti-HER2 therapies targeting particular molecular alterations. The gene discussed is ERBB2; the disease is breast cancer.